Is it realistic that given the high expectations for cyprotex that it could reach 3 per share. Partnerships with the big pharma co's could make these shoot north?

Cyprotex Trading Statement

RNS Number:5916F
Cyprotex PLC
12 October 2007

Cyprotex PLC
(the "Group" or "Cyprotex")


NEWS

12 October 2007

Trading Update : Building Confidence

The Director's confidence with Cyprotex's core operations continued to build
during the third quarter of 2007. The Group enters the final three months of
its year on an optimistic note.

Historically the final quarter has been the strongest period of Cyprotex's
financial year. Moreover, management is pleased to confirm that its customer
base has continued to expand rapidly. Included within the high number of new
MSA (Master Services Agreements) recently signed, and taking the Group's 'active
customer list' beyond 150 pharmaceutical and biotech companies, are several
international majors. Strict confidentiality agreements preclude Cyprotex from
naming individual clients, but the company can now confirm it is currently
contracted to work for six out of the world's 'top ten' global pharmaceutical
companies. The scale and visibility that strong working relationships with such
partners are capable of providing, is key to proving Cyprotex's business plan.
The management is pleased to report an exceptional level of repeat business,
while also being asked to tenders for more long-term contract work as well as
project specific collaborations.

Cyprotex presently holds an adequate cash resource whilst also retaining a
significant, unused banking facility. Based on current momentum, management
sees the opportunity for modest cash generation to expand this 'cushion' still
further during the final three months of the 2007.

For further information:

Cyprotex PLC
Robert Morrison Atwater, CEO
Russell Gibbs, CFO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Numura Code Securities Limited
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires:

WMC Communications
Simon Miller
Tel: +44 (0)20 7930 9030
simon.miller@wmccommunications.com


This information is provided by RNS
The company news service from the London Stock Exchange
END

Press Release 23 November 2007


Cyprotex PLC
("Cyprotex" or "the Company")


Director share purchases

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company
was notified today that Robert Morrison Atwater, the Chairman and Chief
Executive of the Company purchased a total of 175,000 ordinary shares of 0.1p
each in the Company on 22 November 2007 at the following price per share: 75,000
shares at 3.74p; 50,000 shares at 3.78p; and 50,000 shares at 4.00p. Robert
Morrisson Atwater now has a total interest of 1,610,000 ordinary shares in the
Company, which represents 1.16% of the issued share capital of the Company.


- Ends -


For further information:

Cyprotex PLC
Mark Warburton Tel: +44 (0) 1625 505100
iir@cyprotex.com www.cyprotex.com



This information is provided by RNS
The company news service from the London Stock Exchange
END

MACD Indicator turning more towards positive (blue line over red line) for the first time in five weeks. Breakout over 5p looms IMO and Level 2 backs that up. Level 2 closed positive at 3 v 2. 2 MMs on 4.75p, then one on 5p and 2 have already taken positions on 5.25p. Wouldn't be surprise to see more director buying at these low levels.

L2 is 3 v 1...last MM on 4.75p and then 2 on 5p and 2 on 5.25p...Will get more director buying confirmation this week and then breakout over 5p.

4.00-5.00 pence, Level 2 is 1 v 3. On its way to 6p IMO.

4.25-5.00p, L2 is 1 v 1.

4.25-5.25p, L2 is 2 v 4.

4.25-5.25p, L2 is 2 v 4. Should settle here and then push towards 6p tomorrow IMO.

Breakout: MACD Indicator gone positive for the first time in a month.

Another pump and dump by active/chancer6 on three different bulletin
boards today.

His sale of 83062 shares went through late on so this will ensure the
posts will stop until the next pump and dump.

Where's a plumber when you need one?

;-)))

Did say the chairman was going to buy more shares!

Cyprotex Director/PDMR Shareholding




RNS Number:6631I
Cyprotex PLC
28 November 2007







Press Release 28 November 2007


Cyprotex PLC
("Cyprotex" or "the Company")

Director share purchases


Cyprotex PLC (AIM: CRX), the drug discovery technology and information company
was notified today that Robert Morrison Atwater, the Chairman and Chief
Executive of the Company purchased a total of 225,000 ordinary shares of 0.1p
each in the Company on 27 November 2007 at 5.10 pence per share. Robert Morrison
Atwater now has a total interest of 1,835,000 ordinary shares in the Company,
which represents 1.32% of the issued share capital of the Company.



- Ends -



For further information:
Cyprotex PLC
Mark Warburton Tel: +44 (0) 1625 505100
iir@cyprotex.com www.cyprotex.com




This information is provided by RNS
The company news service from the London Stock Exchange
END

I haven't been following this but am very wary of these 'minnows' - to use Cynic's word for them. Just wanted to point out that, as others here would no doubt say, 11.5k is not a huge amount to have spent to acquire the 225,000 shares.

But he also bought 175,000 shares last wk as well. So If my maths is right then that's a total of 400,000 shares!

Toya, don't touch anything Active recommends or posts on, he is an accomplished pump and dumper, end of lesson.

Why on earth would even the Chairman buy shares in this? CRX is famous for 1 moment of fantastic stupidity as far as I'm aware.

As I said, where's a plumber when you need one? The answer os not even a plumber could fix this.

;-))

Thanks PT and BA. I've seen the health warnings that Trader6 had posted here - and BA's lovely plumbing comments; have not the slightest intention of throwing my money away here. Just thought, though, that something should be written to make others think, in case they were blissfully unaware of what you guys already know from experience.

Fundraising Aug08
40million shares - shareholders appear to have subscribed to just 40% - not sure if that's bad - but dilution stalks. . . . . the fundraising collected 1m.
How long will that last, I wonder? + will the Institutions be leaking unsubscribed Stock, creating sp ceiling for a while.
Today sp up a tad, off Lows- but I do wonder?

Is this a stock for feel-good times?

It's not as though they are likely to discover something for the benefit of their own shareholders.....that's where the problem lies....plus most Bios will want to do the easy-bits themselves, I guess.

Worth a look and a longish hold.

I have held these at a loss for over 4years. I thought their model would be useful and "hoped" they would come good.

From the results they are doing so and I think continue to do so.

Difficult to judge, but the company has cash in hand and growth rate should improve rapidly, even in the present environment.

But DYOH

Financial Highlights
Extract from today's RNS

Notwithstanding the significant management changes that took place during the year, the Company has recorded a very progressive financial performance.


*

Revenue for the period increased by 43% to 5.18 million
*

Gross profits rose by 49% to 4.48 million from 3.00 million in 2007
*

Operating profit was positive for the first time in the Company's history at 567,000 against a loss of 496,000 in 2007
*

Earnings per share of 0.36 pence (2007: loss per share of 0.35 pence)
*

Successful fully subscribed Placing and Open Offer raised 1.00 million (0.97 million net of costs)
*

Notwithstanding continuing investment, the year end cash position improved significantly to 1.58 million from the low point recorded at the half year to 30 June 2008 of 0.28 million


New Product and Facilities Development


During the year, the Company undertook a full review of the products and services it offers with several of its largest customers. As a result of that feedback, we have invested in Research and Development programmes and in capital investments to improve both our range of assays and our equipment base. Such investment has been moribund in recent years. The following represents some of the new assays and facilities that have been implemented in 2008 / early 2009.


*

Two new laboratories (720 sq ft in total) have been built and fitted out at our Beech Lane facilities at a total cost of 125,000. These new facilities provide room for a potential further 15 staff and were officially opened in February 2009 by Sir Nicholas Winterton MP DL
*

Early in 2009 a new ABI Sciex QTRAP mass spectrometer was installed at a cost of 250,000. This instrument offers up to 10,000 times greater sensitivity in detection of samples
*

In April 2008, we launched a new product line, Cloe Select, which enables the Company to offer more bespoke, customised assays for our clients. Revenues from this service have steadily risen during the year
*

A new product catalogue was launched in April 2008
*

We have enhanced our range of drug-drug interaction screens. These include introducing our Cloe Select P-gp inhibition assay and extending the number of isoforms in our panel of CYP inhibition screens


These new facilities and assays have been well received by our customers and are already generating new revenue for the business.


We are currently working on development programmes to more fully commercially exploit our software services. We intend to launch an innovative and novel pay-per-use service through a new web based portal called Cloe Gateway. Further investments are planned during 2009.